Peer reviewed journal: VeriStrat test identifies patients with squamous cell lung cancer who are more likely to have improved survival on afatanib (Gilotrif)
VeriStrat® Test identifies patients with squamous cell carcinoma of the lung who are more likely to have improved survival on Afatinib therapy.